1. Home
  2. SNBR vs CABA Comparison

SNBR vs CABA Comparison

Compare SNBR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

HOLD

Current Price

$7.27

Market Cap

186.9M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.17

Market Cap

210.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNBR
CABA
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.9M
210.8M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
SNBR
CABA
Price
$7.27
$2.17
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
$8.00
$14.57
AVG Volume (30 Days)
636.8K
1.8M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,440,882,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$0.99
52 Week High
$19.13
$3.67

Technical Indicators

Market Signals
Indicator
SNBR
CABA
Relative Strength Index (RSI) 45.40 44.27
Support Level $6.99 $2.00
Resistance Level $8.98 $2.23
Average True Range (ATR) 0.55 0.13
MACD -0.25 -0.01
Stochastic Oscillator 15.00 33.67

Price Performance

Historical Comparison
SNBR
CABA

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: